Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta‑analysis

  • Authors:
    • Peng Chen
    • Long Wang
    • Hao Li
    • Bing Liu
    • Zui Zou
  • View Affiliations

  • Published online on: April 11, 2013     https://doi.org/10.3892/ol.2013.1301
  • Pages: 1915-1920
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hypomagnesemia is a serious adverse event for patients treated with cetuximab, an inhibitor of endothelial growth factor receptor (EGFR). However, no significant association has yet been established between cetuximab and hypomagnesemia in randomized controlled clinical trials (RCTs). The present study conducted a systematic review and meta‑analysis of published RCTs to assess the overall risk of hypomagnesemia associated with cetuximab. PubMed, the Cochrane Central Register of Controlled Trials, Embase and the American Society of Clinical Oncology conferences were searched for relevant RCTs. Quantitative analysis was carried out to evaluate the association between hypomagnesemia and cetuximab. A total of 7,045 patients with a variety of advanced cancers from 10 trials were included in the analysis. The overall incidence of grade 3/4 hypomagnesemia in patients receiving cetuximab was 3.9% [95% confidence interval (CI), 2.6‑4.3%]. Patients treated with cetuximab had a significantly increased risk of grade 3/4 hypomagnesemia compared with patients treated with control medication, with a relative risk (RR) of 8.60 (95% CI, 5.08‑14.54). Risk was observed to vary with tumor type. The study concluded that cetuximab is associated with a significant risk of hypomagnesemia in patients with advanced cancer receiving concurrent chemotherapy.
View Figures
View References

Related Articles

Journal Cover

June 2013
Volume 5 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen P, Wang L, Li H, Liu B and Zou Z: Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta‑analysis. Oncol Lett 5: 1915-1920, 2013
APA
Chen, P., Wang, L., Li, H., Liu, B., & Zou, Z. (2013). Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta‑analysis. Oncology Letters, 5, 1915-1920. https://doi.org/10.3892/ol.2013.1301
MLA
Chen, P., Wang, L., Li, H., Liu, B., Zou, Z."Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta‑analysis". Oncology Letters 5.6 (2013): 1915-1920.
Chicago
Chen, P., Wang, L., Li, H., Liu, B., Zou, Z."Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta‑analysis". Oncology Letters 5, no. 6 (2013): 1915-1920. https://doi.org/10.3892/ol.2013.1301